Application No.: 10/539,446

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

(currently amended): An RNA that demonstrates anti-HIV-infection activity
and is employed in prevention and treatment of AIDS, wherein said RNA is selected from the
group consisting of:

a single stranded RNA comprising SEQ-ID-NO:1, SEQ-ID-NO:2 or SEQ ID NO:3;

a single stranded RNA comprising a fragment of SEQ-ID-NO:1, SEQ-ID-NO:2 or SEQ
ID-NO:3;

a double stranded RNA derived by annealing of SEQ ID NO:1 and the complementary sequence thereof, SEQ ID NO:2 and the complementary sequence thereof, or SEQ ID NO:3 and the complementary sequence thereof; and

a double stranded RNA derived by annealing of a fragment of SEQ ID NO:1 and the complementary sequence thereof, a fragment of SEQ ID NO:2 and the complementary sequence thereof, or a fragment of SEQ ID NO:3 and the complementary sequence thereof,

wherein said fragment of SEQ-ID-NO:1, SEQ-ID-NO:2 or SEQ ID NO:3 is selected from the group consisting of

- a 19 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;
- a 20 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;
- a 21 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;
- a 22 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;
- a 23 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

Application No.: 10/539,446

a 24 nt fragment of SEQ ID NO:2 or SEQ ID NO:3;

a 25 nt fragment of SEQ-ID NO:2 or SEQ ID NO:3;

a 26 nt fragment of SEQ ID NO:2 or SEQ ID NO:3;

a 27 nt fragment of SEQ ID NO:3; and

a 28 nt fragment of SEQ ID NO:3;

wherein said 19 nt fragment of SEQ ID NO:1 is selected from the group consisting of ucanugaggaageugeaga, caaugaggaageugeagaa, aaugaggaageugeagaau, augaggaageugeagaaug and ugaggaageugeagaaugg; and

wherein said 19 nt fragment of SEQ-ID NO:2 is selected from the group consisting of ggaagugacauageaggaa, gaagugacauageaggaae, aagugacauageaggaaeu, agugacauageaggaaeua, gugacauageaggaaeuae, ugacauageaggaaeuaeu, gacauageaggaaeuaeua and acauageaggaaeuaeuag.

- (previously presented): The RNA of claim 1, wherein said RNA is modified at its 5' end or 3' end by adding two uracil nucleotides.
- (currently amended): The RNA of claim 1, wherein said RNA is a hairpin RNA consisting of a stem part and a loop part,

wherein said stem part is a double stranded RNA as claimed in claim 1, which is derived by annealing of

SEQ ID NO:1 and the complementary sequence thereof,

SEO ID NO:2 and the complementary sequence thereof,

SEO ID NO:3 and the complementary sequence thereof,

the fragment of SEO ID NO:1 and the complementary sequence thereof,

Application No.: 10/539,446

the fragment of SEQ ID NO:3 and the complementary sequence thereof, or the fragment of SEQ ID NO:3 and the complementary sequence thereof, and wherein said loop is a non-complementary spacer.

 (currently amended): A single-stranded or double-stranded DNA-that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein:

- said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA of claim 1, or its complementary sequence; or
- said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA of claim 2, or its complementary sequence; or
- 3) said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA of claim 3, or its complementary sequence.
- (currently amended): An expression vector that demonstrates anti-HIV
 infection activity and is employed in prevention and treatment of AIDS, wherein said vector
 contains comprising any of the RNA of any one of claims 1-3 or the DNA of claim 4.
- 6. (currently amended): A liposome that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said liposome coats any of encapsulating the RNA of any one of claims 1-3, or the DNA of claim 4.

7-8. (canceled).

Application No.: 10/539,446

9. (currently amended): A liposome that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said liposome coatscncapsulating the vector of Claim 5.

10-12. (canceled).

- 13. (new): An expression vector comprising the DNA of claim 4.
- 14. (new): A liposome encapsulating the DNA of claim 4.
- 15. (new): A liposome encapsulating the vector of Claim 13.